fludarabine teva

Fludarabine Teva is a generic antineoplastic agent containing fludarabine phosphate, a fluorinated nucleotide analog of the antiviral agent vidarabine. It functions as a potent antimetabolite primarily indicated for the treatment of B-cell chronic lymphocytic leukemia (CLL) and is frequently utilized in conditioning regimens for hematopoietic stem cell transplantation and the treatment of various non-Hodgkin lymphomas. The drug's mechanism involves rapid dephosphorylation to 2-fluoro-ara-A, which enters cells and is re-phosphorylated to the active triphosphate form, 2-fluoro-ara-ATP. This metabolite inhibits key enzymes in DNA synthesis, including DNA polymerase alpha, ribonucleotide reductase, and DNA primase, while also being incorporated into the DNA strand to cause premature chain termination and trigger apoptosis. While the original molecule was developed by Schering AG (now Bayer), Teva Pharmaceutical Industries produces this generic version, and Universitair Ziekenhuis Gent has been a notable site for clinical research involving fludarabine-based therapeutic protocols in hematologic malignancies.

Brand names

Fludarabine Teva

Other names

fludarabine phosphate2-fluoro-ara-AMP